Lohit Kumar Kalita1, Chayanika Kalita2, Pabitra Kumar Gogoi3, Umesh Ch. Sarma4
INTRODUCTION
Multiple myeloma is the second most common haematological malignancy in the United States. Recently, it has been reported that globally approximately 0.8 percent of all cancer cases and 0.9 percent of all cancer deaths are attributed to multiple myeloma (MM) and more than 114,000 new cases were diagnosed in 2012 (0.8 percent of total cancer cases). The last decade has seen major advances in understanding the aetiology, biology of multiple myeloma and advances in therapy have improved survival for patients with myeloma making it prototype for the paradigm of transforming into a chronic illness. This study describes epidemiology, pathology, clinical features, diagnosis and prognosis of multiple myeloma. As an increasing body of literature points to an interplay between the MM and its probable risk factors, pathology, diagnosis and prognosis.
